Aspira Pathlab & Diagnostics Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 34.62 million compared to INR 43.73 million a year ago. Revenue was INR 35.62 million compared to INR 44.89 million a year ago. Net loss was INR 7.42 million compared to net income of INR 4.41 million a year ago. Basic loss per share from continuing operations was INR 0.72 compared to basic earnings per share from continuing operations of INR 0.43 a year ago. Diluted loss per share from continuing operations was INR 0.72 compared to diluted earnings per share from continuing operations of INR 0.43 a year ago.
For the nine months, sales was INR 93.87 million compared to INR 110.49 million a year ago. Revenue was INR 97.32 million compared to INR 112.97 million a year ago. Net loss was INR 21.69 million compared to net income of INR 1.71 million a year ago. Basic loss per share from continuing operations was INR 2.11 compared to basic earnings per share from continuing operations of INR 0.17 a year ago. Diluted loss per share from continuing operations was INR 2.11 compared to diluted earnings per share from continuing operations of INR 0.17 a year ago.